Altimmune (ALT) News Today → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free ALT Stock Alerts $7.27 -0.09 (-1.22%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!prnewswire.com - May 7 at 10:17 PMINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investorsbusinesswire.com - May 7 at 8:51 PMThe Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investorsbusinesswire.com - May 7 at 3:06 PMROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALTbusinesswire.com - May 7 at 2:15 PMAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominancecnbc.com - May 7 at 11:33 AMJim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'benzinga.com - May 7 at 9:24 AMAltimmune to Participate at Two Upcoming Investor Conferencesglobenewswire.com - May 7 at 7:30 AMPomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALTprnewswire.com - May 6 at 6:50 PMDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmunestockhouse.com - May 6 at 6:22 PMAmgen stock rallies 13% on GLP-1 weight-loss drug updatemsn.com - May 3 at 6:52 PMAltimmune (ALT) Set to Announce Earnings on Thursdaymarketbeat.com - May 3 at 9:45 AMAltimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024globenewswire.com - May 2 at 7:30 AMAltimmune (NASDAQ:ALT) Shares Up 9.9%marketbeat.com - May 1 at 4:49 PMAltimmune to Participate at Two Upcoming Conferencesglobenewswire.com - May 1 at 7:30 AMBriumvi’s Market Share Growth and TG Therapeutics’ Strong Financial Outlook Justify Buy Ratingmarkets.businessinsider.com - April 30 at 6:47 PMPeering Into Altimmune's Recent Short Interestbenzinga.com - April 30 at 1:47 PMAltimmune (NASDAQ:ALT) Downgraded to Neutral at Guggenheimamericanbankingnews.com - April 30 at 5:32 AMDeutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionmsn.com - April 29 at 9:37 AMAltimmune (NASDAQ:ALT) Downgraded by Guggenheimmarketbeat.com - April 29 at 7:32 AMShort Interest in Altimmune, Inc. (NASDAQ:ALT) Rises By 14.9%marketbeat.com - April 29 at 7:13 AMAltimmune Statement on the Passing of Dr. Stephen Harrisonglobenewswire.com - April 25 at 5:24 PMAltimmune (NASDAQ:ALT) Shares Down 5.3% marketbeat.com - April 24 at 6:15 PM3 Speculative Weight Loss Drug Stocks to Bet On for Big Gainsinvestorplace.com - April 24 at 6:33 AMAltimmune (NASDAQ:ALT) Shares Up 6.5%marketbeat.com - April 22 at 4:46 PMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?marketbeat.com - April 22 at 6:05 AMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (ALT)marketbeat.com - April 22 at 6:05 AMGlobal COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023finance.yahoo.com - April 19 at 12:28 AMAltimmune, Inc. (ALT)finance.yahoo.com - April 18 at 6:22 AMAltimmune (NASDAQ:ALT) Shares Down 7% marketbeat.com - April 15 at 5:31 PMBuy Altimmune's Potential Market Disruption With Pemvidutideseekingalpha.com - April 12 at 1:10 PM3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024investorplace.com - April 11 at 12:24 PMForget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.fool.com - April 9 at 6:45 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?marketbeat.com - April 9 at 6:08 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? marketbeat.com - April 9 at 6:07 AMAltimmune (NASDAQ:ALT) Shares Down 5.2% marketbeat.com - April 8 at 11:59 AMTimelo Investment Management Inc. Grows Stock Position in Altimmune, Inc. (NASDAQ:ALT)marketbeat.com - April 6 at 6:39 PMHC Wainwright Weighs in on Altimmune, Inc.'s Q1 2024 Earnings (NASDAQ:ALT)marketbeat.com - April 4 at 8:48 AMAltimmune (NASDAQ:ALT) Stock Price Down 8.1% After Analyst Downgrademarketbeat.com - April 2 at 10:27 AMThe 3 Best Biotech Stocks to Buy in April 2024investorplace.com - April 1 at 9:09 PMAltimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Ratingmarkets.businessinsider.com - April 1 at 8:08 PMAltimmune (NASDAQ:ALT) Price Target Lowered to $12.00 at HC Wainwrightmarketbeat.com - April 1 at 1:38 PMEli Lilly: Three Threats To Its Huge Rallyseekingalpha.com - March 31 at 4:34 PMA new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drugmsn.com - March 29 at 2:45 PMAltimmune, Inc. (NASDAQ:ALT) Forecasted to Post Q1 2024 Earnings of ($0.30) Per Sharemarketbeat.com - March 29 at 8:16 AMAltimmune (NASDAQ:ALT) Shares Up 5.3%marketbeat.com - March 28 at 3:46 PMAltimmune (NASDAQ:ALT) Receives "Buy" Rating from B. Rileymarketbeat.com - March 28 at 12:33 PMAltimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 28 at 11:06 AMAltimmune says weight loss drug minimized muscle loss in trial results, which may set it apartmsn.com - March 28 at 8:41 AM7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)marketbeat.com - March 28 at 7:22 AMQ4 2023 Altimmune Inc Earnings Callca.finance.yahoo.com - March 28 at 1:04 AM Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address The Department of Defense Has a New Drone Contractor (Ad)The Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes. Click here to see how to invest ALT Media Mentions By Week ALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.380.38▲Average Medical News Sentiment ALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼124▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Korro Bio News KalVista Pharmaceuticals News Fulcrum Therapeutics News Neurogene News Larimar Therapeutics News Arbutus Biopharma News Shattuck Labs News Verve Therapeutics News Astria Therapeutics News Applied Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaBiden replacement revealed?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
